Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up – Still a Buy?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) gapped up before the market opened on Monday . The stock had previously closed at $46.85, but opened at $48.92. Kymera Therapeutics shares last traded at $48.57, with a volume of 64,093 shares changing hands.

Analysts Set New Price Targets

Several research firms recently commented on KYMR. Oppenheimer lifted their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $38.00 to $57.00 in a report on Monday. Stephens initiated coverage on Kymera Therapeutics in a report on Monday, November 18th. They set an “overweight” rating and a $65.00 price target on the stock. UBS Group dropped their price objective on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Finally, Truist Financial reissued a “buy” rating and issued a $53.00 target price (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Three research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $53.40.

Kymera Therapeutics Stock Performance

The business’s fifty day moving average is $46.66 and its two-hundred day moving average is $42.43. The company has a market cap of $3.04 billion, a P/E ratio of -20.05 and a beta of 2.16.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. During the same period in the previous year, the company posted ($0.90) earnings per share. The firm’s quarterly revenue was down 20.9% on a year-over-year basis. Analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other news, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 15.82% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Values First Advisors Inc. purchased a new stake in Kymera Therapeutics in the third quarter valued at about $61,000. Quarry LP acquired a new stake in Kymera Therapeutics in the 3rd quarter worth approximately $95,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after purchasing an additional 504 shares in the last quarter. Comerica Bank raised its holdings in shares of Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after buying an additional 400 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado acquired a new stake in shares of Kymera Therapeutics during the second quarter worth $139,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.